suggests (consistent with expectation) that the infectivity is decreased in peak and duration,
14
further protecting the border.
Furthermore, the level of testing of quarantine workers has been increasing (eg,
19
; which will
find some failures before they have a chance to establish as an outbreak in the community).
There have been other improvements in the quarantine systems over time (eg, improved
security, introduction of mask wearing within quarantine settings, reduction in shared spaces,
improved PPE used by workers, and other procedures as detailed in both countries
20 21
).
Another risk reduction practice would be using better or purpose-built facilities in rural
locations as these have less risk from close contacts in central business district hotels and
within-building spread from poor ventilation systems. Limitations of our analysis include
residual uncertainty around the cause of some outbreaks (eg, the Auckland August 2020), and
imprecision with denominator data on traveller numbers for Australia (eg, some travellers
were moved between states on domestic flights which is not captured in the official data we
used). Additionally, case numbers are constantly changing, due to the number of
reclassifications caused by false positives and duplications.
To substantially reduce the risk of SARS-CoV-2 incursion out of quarantine (until such time
as enough of the population is vaccinated), the most obvious action is to reduce arrivals, or
even suspend arrivals, from high infection locations (as New Zealand temporarily did for
travel from India and other high risk countries in April 2021
22
). Beyond this, there are a range
of other potential improvements in ongoing arrangements and processes as detailed in Table
2. Furthermore, the start of quarantine-free travel between Australia and New Zealand (also
known as a "green zone") in April 2021 provides an opportunity to benchmark COVID-19
border control policies and practices, identify potential improvements in both countries, and
harmonise best practices across the region. The green zone further intertwines the biosecurity
status of both nations and it is therefore even more important to lower the risk of border
failures that could disrupt such travel. This shift from a one-size-fits-all strategy to a risk-
based approach to border management can be summarised as a 'traffic light' approach.
23
Table 2: List of potential policy and operational options for improved COVID-19 control
associated with quarantine systems in Australia and New Zealand, including measures to
reduce the numbers of infected people arriving into quarantine facilities
Policy option Description
Our priority
rankings
1. Cap travel from
high prevalence
countries and/or
suspend for a
period
Reduce the in-flow of travellers by reducing or suspending flights
to Australia and New Zealand (NZ) from very high incidence
countries where the pandemic is out of control. These governments
have the legal powers to put conditions on the existing rights of
their citizens to enter their country of citizenship (ie, on public
health grounds).
Top priority
2. Pre-departure
testing plus/minus
pre-departure
quarantine
Expand existing requirements for pre-departure testing to additional
traveller source countries. Pre-departure testing could be expanded
from not only a PCR test within 72 hours of departure to also add a
rapid test at the airport immediately before departure (given many
infected may have started shedding the virus in the previous 72
hours and most, but not all, of such cases will be detected by a rapid
test even though it has lower sensitivity). Of note is that such
arrangements are considered legally acceptable (see the above row).
Pre-departure quarantine (eg, for a week), would provide additional
Top priority
. CC-BY-NC-ND 4.0 International licenseIt is made available under a
is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)
The copyright holder for this preprint this version posted April 30, 2021. ; https://doi.org/10.1101/2021.02.17.21251946doi: medRxiv preprint